SYNDAX PHARMACEUTICALS INC (SNDX) Stock Analyst Ratings
USA - NASDAQ:SNDX - US87164F1057 - Common Stock
17.73 USD
+2.01 (+12.79%)
17.7977 USD
+0.07 (+0.38%)
ChartMill assigns a Buy % Consensus number of 87% to SNDX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 38.93. This target is 119.57% above the current price.
SNDX was analyzed by 20 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about SNDX.
In the previous month the buy percentage consensus was at a similar level.
SNDX was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-04 | UBS | Maintains | Buy -> Buy |
| 2025-11-04 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-27 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-19 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-10 | Stifel | Reiterate | Buy |
| 2025-09-05 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-04 | Guggenheim | Initiate | Buy |
| 2025-08-05 | BTIG | Maintains | Buy -> Buy |
| 2025-08-05 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-15 | UBS | Maintains | Buy -> Buy |
| 2025-07-10 | Goldman Sachs | Initiate | Buy |
| 2025-05-06 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-05-06 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-03-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-04 | Citigroup | Maintains | Buy -> Buy |
| 2025-03-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-08 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-21 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-11-19 | Citigroup | Maintains | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-07 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-24 | UBS | Initiate | Buy |
| 2024-10-14 | Stifel | Maintains | Buy -> Buy |
| 2024-08-16 | Citigroup | Maintains | Buy -> Buy |
| 2024-08-15 | Barclays | Maintains | Overweight -> Overweight |
SYNDAX PHARMACEUTICALS INC / SNDX FAQ
What is the price target for SNDX stock?
20 analysts have analysed SNDX and the average price target is 38.93 USD. This implies a price increase of 119.57% is expected in the next year compared to the current price of 17.73.
What is the consensus rating for SYNDAX PHARMACEUTICALS INC (SNDX) stock?
The consensus rating for SYNDAX PHARMACEUTICALS INC (SNDX) is 87 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for SNDX stock?
The number of analysts covering SYNDAX PHARMACEUTICALS INC (SNDX) is 20.